Sign Out
Unless patients are monitored for potential increases in blood pressure, Linezolid should not be used in patients with uncontrolled hypertension, pheochromocytoma, or thyrotoxicosis or in patients receiving direct or indirect-acting sympathomimetic agents, vasopressor agents, or dopaminergic agents.
Lactic acidosis has been reported in patients receiving Linezolid. Patients who develop recurrent nausea and vomiting, unexplained acidosis, or a low bicarbonate concentration while receiving Linezolid should undergo immediate medical evaluation.
Seizure have been reported in patients receiving Linezolid. Some cases were reported in patients with a history of seizures or risk factors of seizures.
Symptomatic hypoglycemia has been reported in patients with diabetes mellitus receiving Linezolid concomitantly with insulin or oral antidiabetic agents. Use with caution and closely monitor glucose in diabetic patients.
